DE69704964D1 - Verfahren zur Herstellung von Acryloxypropylsilane - Google Patents

Verfahren zur Herstellung von Acryloxypropylsilane

Info

Publication number
DE69704964D1
DE69704964D1 DE69704964T DE69704964T DE69704964D1 DE 69704964 D1 DE69704964 D1 DE 69704964D1 DE 69704964 T DE69704964 T DE 69704964T DE 69704964 T DE69704964 T DE 69704964T DE 69704964 D1 DE69704964 D1 DE 69704964D1
Authority
DE
Germany
Prior art keywords
acryloxypropylsilanes
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69704964T
Other languages
English (en)
Other versions
DE69704964T2 (de
Inventor
Yoichi Kimae
Shunji Yoshimatsu
Norio Itoda
Takashi Matsuo
Naoki Noda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JNC Corp
Original Assignee
Chisso Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chisso Corp filed Critical Chisso Corp
Application granted granted Critical
Publication of DE69704964D1 publication Critical patent/DE69704964D1/de
Publication of DE69704964T2 publication Critical patent/DE69704964T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/0827—Syntheses with formation of a Si-C bond
    • C07F7/0829—Hydrosilylation reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides
    • C07F7/14—Preparation thereof from optionally substituted halogenated silanes and hydrocarbons hydrosilylation reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1876—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE69704964T 1996-01-24 1997-01-24 Verfahren zur Herstellung von Acryloxypropylsilane Expired - Lifetime DE69704964T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8031449A JP2978435B2 (ja) 1996-01-24 1996-01-24 アクリロキシプロピルシランの製造方法

Publications (2)

Publication Number Publication Date
DE69704964D1 true DE69704964D1 (de) 2001-07-05
DE69704964T2 DE69704964T2 (de) 2001-11-15

Family

ID=12331571

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69704964T Expired - Lifetime DE69704964T2 (de) 1996-01-24 1997-01-24 Verfahren zur Herstellung von Acryloxypropylsilane

Country Status (4)

Country Link
US (1) US5750753A (de)
EP (1) EP0786464B1 (de)
JP (1) JP2978435B2 (de)
DE (1) DE69704964T2 (de)

Families Citing this family (503)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1161451A4 (de) 1999-02-26 2006-05-17 Human Genome Sciences Inc Menschliches alpha-endokin und verfahren zu seiner verwendung
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20060073509A1 (en) * 1999-11-18 2006-04-06 Michael Kilpatrick Method for detecting and quantitating multiple subcellular components
EP2213743A1 (de) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
CA2407377A1 (en) * 2000-04-24 2001-11-01 Yale University Dna & protein binding miniature proteins
US7495070B2 (en) * 2000-04-24 2009-02-24 Yale University Protein binding miniature proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
KR101155294B1 (ko) 2000-06-16 2013-03-07 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
TWI327599B (en) 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
EP1366058B1 (de) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
JP4688311B2 (ja) * 2001-02-22 2011-05-25 東レ・ダウコーニング株式会社 （メタ）アクリル官能基含有有機ケイ素化合物の製造方法
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CA2469843A1 (en) * 2001-06-04 2002-12-12 Ikonisys Inc. Method for detecting infectious agents using computer controlled automated image analysis
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
CA2492823A1 (en) * 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
US20070166704A1 (en) * 2002-01-18 2007-07-19 Fei Huang Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways
DE60329020D1 (de) 2002-03-01 2009-10-08 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten
ES2320115T3 (es) * 2002-03-01 2009-05-19 Siemens Healthcare Diagnostics Inc. Ensayos para monitorear a un paciente con cancer con base en los niveles de los componentes analitos del sistema activador de plasminogeno en muestras de fluido corporal.
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
EP1499352A4 (de) 2002-04-12 2006-10-11 Medimmune Inc Rekombinante anti-interleukin-9-antikörper
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
FR2841244B1 (fr) * 2002-06-21 2007-10-05 Rhodia Chimie Sa Procede de preparation d'organo dialkylalcoxysilane
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
EP1585815A4 (de) * 2003-01-21 2006-02-22 Bristol Myers Squibb Co Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2457538T3 (es) 2003-02-20 2014-04-28 Seattle Genetics, Inc. Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
WO2004085648A2 (en) * 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
EP2316487B1 (de) 2003-04-11 2014-06-11 MedImmune, LLC Rekombinante IL-9 Antikörper und ihre Verwendung
JP2008500005A (ja) * 2003-07-15 2008-01-10 バロス リサーチ インスティテュート 癌及び感染症の免疫療法のための組成物及び方法
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2534661A1 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
JP4524554B2 (ja) 2003-09-25 2010-08-18 信越化学工業株式会社 γ，δ−不飽和カルボン酸及びそのシリルエステルの製造方法、カルボキシル基を有する有機ケイ素化合物及びその製造方法
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
AU2004292393C1 (en) 2003-11-21 2011-08-04 Ucb Pharma S.A. Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2005097184A2 (en) * 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP2207033B1 (de) 2004-04-15 2014-06-18 University of Florida Research Foundation, Inc. Neuralproteine als Biomarker für Verletzungen des Nervensystems und anderen neuralen Störungen
ES2442386T3 (es) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
EP2474317A1 (de) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Behandlung von Zuständen einhergehend mit Demyelisation
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
EP2329714A1 (de) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Einfluss von TAJ in den neuronalen Funktionen
EP3073267A1 (de) 2004-09-21 2016-09-28 Medimmune, Inc. Antikörper gegen und verfahren zur herstellung von impfstoffen für respiratorische synzytialvirus
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CA2599589A1 (en) 2005-02-07 2006-08-17 Genenews,Inc. Mild osteoarthritis biomarkers and uses thereof
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
CA2597924C (en) 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
DK1871418T3 (da) 2005-04-19 2014-06-10 Seattle Genetics Inc Humaniserede anti-cd70-bindende midler og anvendelser deraf
EA013821B1 (ru) * 2005-05-25 2010-08-30 Кьюрдм, Инк. Проостровковые пептиды человека, их производные и аналоги и способы их применения
EP1893647A2 (de) 2005-06-23 2008-03-05 MedImmune, Inc. Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
CN103145838A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
WO2007008604A2 (en) * 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
CA2614421A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8846195B2 (en) * 2005-07-22 2014-09-30 Canon Nanotechnologies, Inc. Ultra-thin polymeric adhesion layer
US8557351B2 (en) 2005-07-22 2013-10-15 Molecular Imprints, Inc. Method for adhering materials together
NZ565631A (en) 2005-08-03 2011-01-28 Adelaide Res & Innovation Pty Polysaccharide synthases
EP2500355A3 (de) 2005-08-19 2012-10-24 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
ES2382879T3 (es) * 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
ES2542501T3 (es) * 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
TW200730825A (en) 2005-10-21 2007-08-16 Genenews Inc Method and apparatus for correlating levels of biomarker products with disease
EP1959979A4 (de) 2005-11-04 2010-01-27 Biogen Idec Inc Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
CN101500592A (zh) 2005-11-07 2009-08-05 斯克利普斯研究院 控制组织因子信号转导特异性的组合物和方法
ES2491118T3 (es) 2005-11-28 2014-09-05 Zymogenetics, Inc. Antagonistas de IL-21
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
WO2007062852A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
KR101422523B1 (ko) 2005-12-09 2014-07-24 유씨비 파마, 에스.에이. 사람 ｉｌ­6에 특이성을 지니는 항체 분자
CN101420977B (zh) 2006-01-27 2016-08-10 比奥根Ma公司 Nogo受体拮抗剂
EP1987361A4 (de) * 2006-01-30 2009-03-04 Invitrogen Corp Zusammensetzungen und verfahren zur erkennung und quantifizierung toxischer substanzen in krankheitsstadien
EP2540741A1 (de) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
EP2815764A1 (de) 2006-06-14 2014-12-24 Macrogenics, Inc. Verfahren zur Behandlung von Autoimmunerkrankungen anhand von monoklonalen Antikörpern mit reduzierter Toxizität
EP2029173B1 (de) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2658276A1 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody for the treatment of cancer
TW201343676A (zh) 2006-08-28 2013-11-01 Kyowa Hakko Kirin Co Ltd 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
DK3339445T3 (da) 2006-09-08 2020-10-19 Abbvie Bahamas Ltd Interleukin -13 bindende proteiner
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
MX2009007375A (es) 2007-01-09 2009-07-21 Biogen Idec Inc Anticuerpos sp35 y usos de los mismos.
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8685666B2 (en) * 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008101184A2 (en) * 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
EP3118221B1 (de) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteine
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
MY166021A (en) 2007-03-22 2018-05-21 Biogen Ma Inc Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof
EP2077859A4 (de) 2007-03-30 2010-11-24 Medimmune Llc Antikörper-formulierung
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
SG194368A1 (en) 2007-05-04 2013-11-29 Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa Engineered rabbit antibody variable domains and uses thereof
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
PT2068927E (pt) 2007-05-14 2016-02-10 Medimmune Llc Métodos para reduzir os níveis de eosinófilos
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
KR101599735B1 (ko) 2007-06-21 2016-03-07 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
WO2009020477A1 (en) * 2007-08-06 2009-02-12 Yale University Modified miniature proteins
EP2559700A3 (de) * 2007-08-30 2013-03-13 CureDM Group Holdings, LLC Zusammensetzungen und Verfahren zur Anwendung von Proinselzellpeptiden und ihren Analoga
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
EP2195341B1 (de) 2007-09-26 2017-03-22 UCB Biopharma SPRL Fusionsantikörper mit dualer spezifität
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
JP5767475B2 (ja) 2007-11-05 2015-08-19 メディミューン，エルエルシー 強皮症の治療方法
AU2008325107B2 (en) * 2007-11-08 2015-04-23 Biogen Ma Inc. Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
EP2227556B1 (de) 2007-11-19 2014-08-27 Celera Corporation Lungenkrebs-marker und deren verwendungen
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
WO2009088105A1 (en) 2008-01-11 2009-07-16 Gene Techno Science Co., Ltd. HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
MX2010010737A (es) 2008-04-02 2010-12-20 Macrogenics Inc Anticuerpos especificos para her2/neu y metodos para utilizar los mismos.
ES2589912T3 (es) 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
ES2588194T3 (es) 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
WO2009131256A1 (en) 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
US20090269786A1 (en) * 2008-04-25 2009-10-29 The Board Of Trustees Of The University Of Illinois RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
JP5141897B2 (ja) * 2008-04-30 2013-02-13 信越化学工業株式会社 クロロシリル基含有エチルノルボルネン化合物の製造方法
JP5624535B2 (ja) 2008-05-02 2014-11-12 シアトル ジェネティクス，インコーポレーテッド 低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
KR101603917B1 (ko) 2008-05-09 2016-03-17 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
EP2304439A4 (de) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt-antikörper
EP2297208A4 (de) 2008-06-03 2012-07-11 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US20110081347A1 (en) 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
JP2011527579A (ja) 2008-07-08 2011-11-04 アボット・ラボラトリーズ プロスタグランジンｅ２結合タンパク質およびこの使用
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
EP2350270B1 (de) 2008-10-24 2018-03-07 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Menschliche ebolavirus-spezies sowie zusammensetzungen und verfahren dafür
US8361546B2 (en) * 2008-10-30 2013-01-29 Molecular Imprints, Inc. Facilitating adhesion between substrate and patterned layer
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
KR101245929B1 (ko) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 항체 매개된 골질 재생
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
SG173620A1 (en) 2009-02-17 2011-09-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
AR075798A1 (es) 2009-03-05 2011-04-27 Abbott Lab Proteinas de union a il-17 (interleuquina 17)
EP2405920A1 (de) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue therapie gegen angstzustände
KR101667227B1 (ko) 2009-03-10 2016-10-18 가부시키가이샤 진 테크노 사이언스 인간화된 ｋ33ｎ 단일 클론 항체의 제조, 발현 및 해석
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
BRPI1015234A2 (pt) 2009-06-22 2018-02-20 Medimmune Llc regiões fc projetadas para conjugação sítio específica.
CN102656189B (zh) 2009-08-13 2014-10-08 克鲁塞尔荷兰公司 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
MX2012002605A (es) 2009-08-29 2012-04-02 Abbott Lab Proteinas terapeutico de union a dll4.
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
JP6095368B2 (ja) 2009-10-27 2017-03-15 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
CA2780024A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
US20110165412A1 (en) * 2009-11-24 2011-07-07 Molecular Imprints, Inc. Adhesion layers in nanoimprint lithograhy
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
RU2605928C2 (ru) 2010-03-02 2016-12-27 Эббви Инк. Терапевтические dll4-связывающие белки
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP2561076A1 (de) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation von xrn1
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
US20110293629A1 (en) 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
CA3062786C (en) 2010-07-09 2022-04-19 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
SI3333188T1 (sl) 2010-08-19 2022-04-29 Zoetis Belgium S.A. Protitelesa proti NGF in njihova uporaba
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
KR20130133247A (ko) 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
EP2654790B1 (de) 2010-12-22 2019-02-06 Teva Pharmaceuticals Australia Pty Ltd Modifizierter antikörper mit verbesserter halbwertzeit
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
EA037071B1 (ru) 2011-01-14 2021-02-02 Юсб Байофарма Срл Молекулы антител, которые связываются с il-17a и il-17f
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
CA2836873C (en) 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
EP2717911A1 (de) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
DK2718320T3 (en) 2011-06-10 2018-03-26 Medimmune Ltd ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
CN103649121B (zh) 2011-06-28 2016-10-19 牛津生物疗法有限公司 针对adp-核糖基环化酶2的抗体
RS55716B1 (sr) 2011-06-28 2017-07-31 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
CN103857411A (zh) 2011-07-13 2014-06-11 阿布维公司 使用抗il-13抗体治疗哮喘的方法和组合物
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2756094B1 (de) 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antikörper und ihre verwendungen
AU2012306341B2 (en) 2011-09-09 2017-08-31 Cambridge Enterprise Limited Anti-Siglec-15 antibodies and uses thereof
CA2853258A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773373B1 (de) 2011-11-01 2018-08-22 Bionomics, Inc. Verfahren zur blockierung eines krebsstammzellenwachstums
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
SI2776065T1 (sl) 2011-11-07 2020-10-30 Medimmune Limited Kombinacijske terapije z uporabo molekul, ki vežejo anti-Pseudomonas Psl in PcrV
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
HUE037142T2 (hu) 2011-11-11 2018-08-28 Ucb Biopharma Sprl Albumin-kötõ ellenanyagok és kötõfragmenseik
EP2785726B1 (de) 2011-12-02 2018-08-01 Dow Silicones Corporation Esterfunktionelle silane sowie ihre herstellung und verwendung und verwendung von iminiumverbindungen als phasentransferkatalysatoren
CN107459576A (zh) 2011-12-14 2017-12-12 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
CN107880124B (zh) 2012-01-27 2021-08-13 艾伯维德国有限责任两合公司 用于诊断和治疗与神经突变性相关的疾病的组合物和方法
AU2013216863B2 (en) 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
ES2690786T3 (es) 2012-02-15 2018-11-22 Novo Nordisk A/S Anticuerpos que se unen a la proteína 1 de reconocimiento de peptidoglicano
EP3196214B1 (de) 2012-02-15 2019-07-31 Novo Nordisk A/S Antikörper, die den auslösenden rezeptor binden und blockieren, der auf myeloid-zellen-1 (trem-1) exprimiert ist
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
US9421250B2 (en) 2012-03-23 2016-08-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
ES2766836T3 (es) 2012-05-15 2020-06-15 Eisai Inc Métodos para el tratamiento de cáncer gástrico
US10048253B2 (en) 2012-06-28 2018-08-14 Ucb Biopharma Sprl Method for identifying compounds of therapeutic interest
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2869818A1 (de) 2012-07-06 2015-05-13 Novartis AG Kombination aus einem phosphinositid-3-kinase-hemmer und einem hemmer der il-8-/cxcr-interaktion
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
EP2906241B1 (de) 2012-10-12 2020-01-08 The Brigham and Women's Hospital, Inc. Verbesserung der immunreaktion
UY35110A (es) 2012-11-01 2014-05-30 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
KR20150100715A (ko) 2012-12-21 2015-09-02 앰플리뮨, 인크. 항-h7cr 항체
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
MX2015012825A (es) 2013-03-14 2016-06-10 Abbott Lab Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
CA2906130A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Anti-egfr antibody drug conjugate formulations
AU2014240012A1 (en) 2013-03-15 2015-09-24 Abbvie Inc. Antibody drug conjugate (ADC) purification
JP2016521283A (ja) 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 成長因子モジュレーションのための組成物および方法
BR112015029395A2 (pt) 2013-05-24 2017-09-19 Medimmune Llc Anticorpos anti-b7-h5 e seus usos
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
EP3632467B1 (de) 2013-06-07 2023-09-27 Duke University Inhibitoren des komplementfaktors h
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
PL3041507T3 (pl) 2013-08-26 2021-11-15 Biontech Research And Development, Inc. Kwasy nukleinowe kodujące ludzkie przeciwciała przeciwko sialyl-lewis a
WO2015066027A2 (en) 2013-10-28 2015-05-07 Dots Devices, Inc. Allergen detection
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
WO2015153916A1 (en) 2014-04-04 2015-10-08 Bionomics, Inc. Humanized antibodies that bind lgr5
ES2869459T3 (es) 2014-05-16 2021-10-25 Medimmune Llc Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
SI3154583T1 (sl) 2014-06-04 2021-05-31 Biontech Research And Development, Inc. Humana monoklonalna protitelesa na gangliozid GD2
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
EP3157535A1 (de) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
HRP20240088T1 (hr) 2014-07-17 2024-04-12 Novo Nordisk A/S Mutageneza usmjerena na mjesto protutijela trem-1 za smanjenje viskoziteta
EP3197557A1 (de) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats und brustrkrebs
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
PL3218005T3 (pl) 2014-11-12 2023-05-02 Seagen Inc. Związki oddziałujące z glikanami i sposoby ich zastosowania
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3789039A1 (de) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US10858448B2 (en) 2015-02-02 2020-12-08 I2 Pharmaceuticals, Inc. Anti-surrogate light chain antibodies
BR112017015880A2 (pt) 2015-03-03 2018-07-31 Kymab Ltd anticorpos, usos e métodos
EP3273994B1 (de) 2015-03-27 2021-12-01 University of Southern California Car-t-zelltherapie gegen lhr zur behandlung von soliden tumoren
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016172769A1 (en) 2015-04-29 2016-11-03 University Of South Australia Compositions and methods for administering antibodies
WO2016179518A2 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
EP3292152A1 (de) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40-antikörper und verfahren zur verwendung davon
CN113940996A (zh) 2015-05-27 2022-01-18 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
EP4047022A1 (de) 2015-05-29 2022-08-24 AbbVie Inc. Anti-cd40-antikörper und verwendungen davon
KR102492532B1 (ko) 2015-05-29 2023-01-30 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
AU2016270474A1 (en) 2015-06-04 2018-01-04 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
CN109310744A (zh) 2015-09-23 2019-02-05 赛通免疫有限责任公司 用于免疫治疗的flt3定向car细胞
SG10202112586WA (en) 2015-10-27 2021-12-30 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3383908A1 (de) 2015-12-02 2018-10-10 Stsciences, Inc. Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
KR20180086246A (ko) 2015-12-02 2018-07-30 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
CN108291030B (zh) 2015-12-07 2021-01-05 美国陶氏有机硅公司 使用铱络合物催化剂氢化硅烷化羧酸烷基酯和氢封端的有机硅氧烷寡聚物的方法和组合物
EP3386542B1 (de) 2015-12-10 2020-11-18 Katholieke Universiteit Leuven Anti-adamts13-antikörper und deren verwendung zur behandlung oder verhütung von hämorrhagischen störungen aufgrund einer ventrikulären unterstützungsvorrichtung
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
KR102439395B1 (ko) 2016-03-10 2022-09-05 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
AU2017239038B2 (en) 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CN110249226B (zh) 2016-10-03 2023-08-25 雅培实验室 评估患者样品中gfap状态的改进方法
TWI773694B (zh) 2016-10-11 2022-08-11 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
KR20190107656A (ko) 2016-11-02 2019-09-20 이뮤노젠 아이엔씨 항체-약물 콘주게이트 및 parp 억제제로 병용 치료
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
EP3551660B1 (de) 2016-12-07 2023-09-13 Agenus Inc. Anti-ctla-4-antikörper und verfahren zur verwendung davon
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
EP3610268A1 (de) 2017-04-15 2020-02-19 Abbott Laboratories Verfahren zur unterstützung bei der hyperakuten diagnose und bestimmung von traumatischen hirnverletzungen in einem menschlichen patienten mit frühbiomarkern
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
FI3618863T3 (fi) 2017-05-01 2023-09-01 Agenus Inc Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN110651190A (zh) 2017-05-25 2020-01-03 雅培实验室 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
AU2018275235B2 (en) 2017-05-30 2024-07-18 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
EP3630835A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
EP3649474A1 (de) 2017-07-03 2020-05-13 Abbott Laboratories Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
MX2020000342A (es) 2017-07-11 2020-08-17 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos.
EP3684811A2 (de) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multispezifitätsbinder von cxc-chemokinen und ihre verwendung
JP7437301B2 (ja) 2017-08-25 2024-02-22 ファイヴ プライム セラピューティクス インク Ｂ７－ｈ４抗体及びその使用方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
AU2018361957B2 (en) 2017-10-31 2023-05-25 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2020005473A (es) 2017-11-27 2020-08-27 Purdue Pharma Lp Anticuerpos humanizados que se dirigen al factor tisular humano.
CA3067055A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CN112262155A (zh) 2018-03-14 2021-01-22 表面肿瘤学公司 结合cd39的抗体及其用途
CA3093740A1 (en) 2018-03-22 2019-09-26 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
KR20200139219A (ko) 2018-04-02 2020-12-11 브리스톨-마이어스 스큅 컴퍼니 항-trem-1 항체 및 이의 용도
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
KR102661891B1 (ko) 2018-05-10 2024-05-23 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
AU2019289176A1 (en) 2018-06-18 2020-12-24 Oxford University Innovation Limited Gremlin-1 antagonist for the prevention and treatment of cancer
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
US12006357B2 (en) 2018-06-26 2024-06-11 Mor Research Applications Ltd. Transthyretin antibodies and uses thereof
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
US20210309746A1 (en) 2018-08-09 2021-10-07 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
JP7539897B2 (ja) 2019-01-16 2024-08-26 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトｃｄ１３７に結合する抗体の製剤およびその使用
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
ES2978570T3 (es) 2019-02-26 2024-09-16 Inspirna Inc Anticuerpos anti-MERTK de alta afinidad y sus usos
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
CN114867751A (zh) 2019-08-12 2022-08-05 阿帕特夫研究和发展有限公司 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
CN114641501A (zh) 2019-09-04 2022-06-17 Y生物股份有限公司 抗vsig4抗体或抗原结合片段及其用途
WO2021055329A1 (en) 2019-09-16 2021-03-25 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
CA3151078A1 (en) 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
JP7298446B2 (ja) * 2019-11-07 2023-06-27 信越化学工業株式会社 アクリロイルオキシ基またはメタクリロイルオキシ基を有する有機ケイ素化合物の製造方法
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CA3160204A1 (en) 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
EP4100435A1 (de) 2020-02-05 2022-12-14 Larimar Therapeutics, Inc. Tat-peptidbindende proteine und ihre verwendungen
EP4103609A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd7
EP4103612A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
US20230192900A1 (en) 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
EP4103610A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Anti-cd4-ctla4 bispezifische antikörper
MX2022010021A (es) 2020-02-18 2022-11-09 Alector Llc Anticuerpos de pilra y sus metodos de uso.
EP4114445A1 (de) 2020-03-06 2023-01-11 Ona Therapeutics S.L. Anti-cd36-antikörper und ihre verwendung zur behandlung von krebs
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
BR112022023088A2 (pt) 2020-05-17 2022-12-20 Astrazeneca Uk Ltd Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos
WO2022018040A2 (en) 2020-07-20 2022-01-27 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
CA3188349A1 (en) 2020-08-04 2022-02-10 A. Scott Muerhoff Improved methods and kits for detecting sars-cov-2 protein in a sample
US11725052B2 (en) 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
EP4229081A1 (de) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20240301086A1 (en) 2020-12-01 2024-09-12 Aptevo Research And Development Llc Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
EP4277664A1 (de) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antikörper-pyrrolobenzodiazepinderivat-konjugat
TW202245844A (zh) 2021-01-13 2022-12-01 紀念斯隆凱特琳癌症中心 抗dll3抗體-藥物結合物
KR20230156727A (ko) 2021-03-03 2023-11-14 피에르 파브르 메디카먼트 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
IL308198A (en) 2021-05-07 2024-01-01 Surface Oncology Llc Anti-IL-27 antibodies and uses thereof
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
US20240118279A1 (en) 2021-06-14 2024-04-11 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
IL309405A (en) 2021-06-29 2024-02-01 Seagen Inc Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
WO2023007472A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
CA3232176A1 (en) 2021-09-30 2023-04-06 Beth MCQUISTON Methods and systems of diagnosing brain injury
WO2023069844A1 (en) 2021-10-21 2023-04-27 Dow Global Technologies Llc Method for promoting hydrosilylation reaction to prepare ester-functional siloxane oligomers
EP4177266A1 (de) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralisierende humane anti-sars-cov-2-antikörper
AU2022413677A1 (en) 2021-12-17 2024-06-27 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
AU2023216317A1 (en) 2022-02-04 2024-09-05 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658866A (en) * 1968-08-26 1972-04-25 Toray Industries Catalyst for a hydrosilation reactor
JPS5024947B1 (de) 1969-04-02 1975-08-20
BE792530A (fr) * 1971-12-10 1973-03-30 Ceskoslovenska Akademie Ved Procede de preparation de composes organiques non satures de silicium
JPS5024947A (de) * 1972-02-09 1975-03-17
US3925434A (en) 1975-01-22 1975-12-09 Union Carbide Corp The reaction of chlorosilanes with unsaturated organic compounds
DE2810032C2 (de) * 1977-03-23 1983-03-24 Chisso Corp., Osaka Verfahren zur Herstellung von monosubstituierten Dichlorsilanen
JPS5629873A (en) * 1979-08-16 1981-03-25 Ricoh Co Ltd Head loading device
US4292433A (en) * 1980-10-31 1981-09-29 Chisso Corporation Method for producing 3-chloropropyltrichlorosilane
JPS59213728A (ja) * 1983-05-17 1984-12-03 Mitsubishi Electric Corp シリコ−ン化合物の製造法
JPS60213728A (ja) 1984-04-06 1985-10-26 Ishikawajima Harima Heavy Ind Co Ltd 微粉炭流量の計測方法
JPS61236786A (ja) * 1985-04-11 1986-10-22 Shin Etsu Chem Co Ltd 環状シロキサンおよびその製造方法
US4614812A (en) * 1985-12-31 1986-09-30 Union Carbide Corporation Novel process for promoting hydrosilation reactions using a second hydrosilane
US5191103A (en) * 1991-12-30 1993-03-02 Union Carbide Chemicals & Plastics Technology Corporation Process and composition for promoting hydrosilylation reactions using sterically hindered nitrogen-containing and phosphorus-containing compounds
JP2851477B2 (ja) * 1992-03-25 1999-01-27 東レ・ダウコーニング・シリコーン株式会社 アクリロキシ基またはメタクリロキシ基含有有機ケイ素化合物の製造方法

Also Published As

Publication number Publication date
JPH09202791A (ja) 1997-08-05
EP0786464B1 (de) 2001-05-30
DE69704964T2 (de) 2001-11-15
US5750753A (en) 1998-05-12
JP2978435B2 (ja) 1999-11-15
EP0786464A1 (de) 1997-07-30

Similar Documents

Publication Publication Date Title
DE69704964D1 (de) Verfahren zur Herstellung von Acryloxypropylsilane
DE69705161D1 (de) Verfahren zur Herstellung von Bisphenol
DE69713022D1 (de) Verfahren zur Herstellung von Unterkleidung
DE69508310D1 (de) Verfahren zur Herstellung von Mikrolinsen
DE59707913D1 (de) Kontinuierliches Verfahren zur Herstellung von gamma- Aminopropyltrialkoxysilanen
DE69618022D1 (de) Verfahren zur Herstellung von Schleifmitteln
DE69802534D1 (de) Verfahren zur herstellung von fluorkohlenwasserstoffen
DE69703923D1 (de) Verfahren zur Herstellung von Polyester
DE69510596D1 (de) Verfahren zur Herstellung von Organooxysilane
DE69502384D1 (de) Prozess zur herstellung von polyarylenetherketonen
DE69725675D1 (de) Verfahren zur Herstellung von Metallocenen
DE69611484D1 (de) Verfahren zur Herstellung von Phenol
DE69702550D1 (de) Verfahren zur Herstellung von peroxiperfluoropolyxyalkylene
DE69735433D1 (de) Verfahren zur herstellung von substituierten pyridinen
DE59707046D1 (de) Kontinuierliches Verfahren zur Herstellung von 4-Aminopiperidinen
DE69700509D1 (de) Verfahren zur Herstellung von Allylsilanen
DE69712157D1 (de) Verfahren zur Herstellung von Acrylnitril
DE69811870D1 (de) Verfahren zur Herstellung von Methanol
DE59702177D1 (de) Verfahren zur Herstellung von Hydroxymethylcyclopropan
DE59610221D1 (de) Verfahren zur Herstellung von 2-Acetyl-gamma-butyrolacton
DE69703764D1 (de) Verfahren zur Herstellung von N-Acetonylbenzamide
DE69711326D1 (de) Verfahren zur Herstellung von Ethylaminen
DE69611331D1 (de) Verfahren zur Herstellung von S-Phenyl-L-Cystein
DE69530176D1 (de) Verfahren zur Herstellung von Protein
DE59800130D1 (de) Verfahren zur Herstellung von Organosilazanen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 786464

Country of ref document: EP

Representative=s name: MUELLER-BORE & PARTNER, PATENTANWAELTE, EUROPEAN P